



## **Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland**

May 14, 2010

ROCKVILLE, Md., May 13, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland's (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland's biotechnology community as well as its presence and leadership within the state.

"It is an honor to represent Emergent BioSolutions, a company composed of talented and hardworking individuals committed to the corporate mission of protecting life," said Fuad El-Hibri, chairman and chief executive officer, who received the award on behalf of the company.

For 22 years, TCM has recognized companies that have helped establish Maryland's thriving technology community. This year's theme "Building Something Great Together" focuses on the tremendous growth and future outlook for the technology community.

"The theme, 'Building Something Great Together,' is meaningful because Emergent's success is built on teamwork and collaboration," Mr. El-Hibri continued. "It also acknowledges the role that businesses play in contributing to the State's economic and job growth. Emergent is proud to be amongst the technology and life sciences companies that have chosen Maryland as its home."

The criteria for the Biotechnology Firm of the Year Award include: achieving significant and measurable success, contributing to the advancement of biosciences through cutting-edge research and development, crisply executing a growth strategy, and helping foster a vibrant biotech community.

TCM is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM's mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed.

### **About Emergent BioSolutions Inc.**

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax<sup>(R)</sup> (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

SOURCE: Emergent BioSolutions Inc.

### **Emergent BioSolutions**

#### **Investors:**

Robert G. Burrows, Vice President, Investor Relations

+1-301-795-1877

[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

#### **Media:**

Tracey Schmitt, Vice President, Corporate Communications

+1-301-795-1800

[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)